Elzonris™ (tagraxofusp-erzs) – New orphan drug approval
December 21, 2018 - The FDA announced the approval of Stemline Therapeutics’ Elzonris (tagraxofusp-erzs), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Download PDF
